Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Key Points

• CFO Alex Thurman sold 10,000 shares of Glaukos at an average price of $140 under a pre-arranged Rule 10b5-1 plan, generating $1.4M and reducing his stake by 18.63% to 43,681 shares (valued ~ $6.12M).
• Glaukos reported a quarterly beat with revenue of $150.6M (up 41.2% year‑over‑year) and EPS of -$0.18 vs. a -$0.30 estimate, though the company remains unprofitable with negative net margin and ROE.
• Shares slipped about 3% to $135.98 on higher volume, while analysts are generally positive — consensus rating "Moderate Buy" with a consensus target of $138.85 and multiple firms raising price targets.

Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $140.00, for a total value of $1,400,000.00. Following the transaction, the chief financial officer directly owned 43,681 shares in the company, valued at $6,115,340. The trade was a 18.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Glaukos Stock Down 3.0%

NYSE GKOS traded down $4.24 during mid-day trading on Monday, hitting $135.98. The company's stock had a trading volume of 942,743 shares, compared to its average volume of 790,624. The company's 50 day simple moving average is $114.02 and its 200 day simple moving average is $108.01. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $146.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $7.96 billion, a price-to-earnings ratio of -41.46 and a beta of 0.94.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share. The business's revenue was up 41.2% on a year-over-year basis. Analysts anticipate that Glaukos Corporation will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GKOS. BTIG Research raised their price target on shares of Glaukos from $131.00 to $141.00 and gave the company a "buy" rating in a research report on Thursday. Needham & Company LLC increased their price objective on Glaukos from $127.00 to $136.00 and gave the stock a "buy" rating in a research note on Thursday. Piper Sandler restated an "overweight" rating and issued a $165.00 target price on shares of Glaukos in a report on Wednesday, January 14th. JPMorgan Chase & Co. raised their target price on Glaukos from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Thursday. Finally, Wall Street Zen upgraded Glaukos from a "hold" rating to a "buy" rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $138.85.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. First Horizon Corp lifted its holdings in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 223 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Glaukos in the fourth quarter valued at approximately $28,000. UMB Bank n.a. lifted its holdings in shares of Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 158 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Glaukos by 111.4% in the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier's stock valued at $46,000 after purchasing an additional 215 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.